Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 123

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 123
---
 Bio in September 2021, and Amunix Pharmaceuticals, Inc in February 2022; the deconsolidation of EUROAPI in May 2022, the acquisitions of Provention Bio, Inc. QRIB Intermediate Holdings, LLC. in 2023; and the acquisitions of Inhibrx, Inc in 2024; and the sale of Opella, expected to close in the second quarter of 2025 at the earliest ( for a description of the main such events over the past three years, refer to “A. History and Development of the Company” above) . In certain countries, we carry on some of our business operations through joint ventures with local partners. In addition, we have entered into worldwide collaboration agreements, in particular with Regeneron on Dupixent and Kevzara and with AztraZeneca on Beyfortus. For further information, refer to Note C. “Principal Alliances” to our consolidated financial statements, included at Item 18. of this annual report. C.2. Internal organization of activities Sanofi and its subsidiaries collectively form a group organized around a Biopharma operating segment (Immunology & Inflammation, Rare diseases, Neurology, Oncology, Other medicines, Vaccines). Opella, our former Consumer Healthcare operating segment, is now classified as a discontinued operation in accordance with IFRS 5. See “Item 5. Operating and Financial Review and Prospects — A.1.1. 2024 Overview”. Within Sanofi, responsibility for R&D rests with Sanofi and Genzyme Corporation for medicines, and with Sanofi Pasteur and Sanofi Pasteur, Inc. for vaccines . However, within our integrated R&D organization, strategic priorities are set and R&D efforts coordinated on a worldwide scale. In fulfilling their role in R&D, the aforementioned companies subcontract R&D to those of their subsidiaries that have the necessary resources. They also license patents, manufacturing know-how and trademarks to certain of their French and foreign subsidiaries. Those licensee subsidiaries manufacture, commercialize and distribute the majority of our products, either directly or via local distribution entities. Our industrial property rights, patents and trademarks are mainly held by the following companies: • Biopharma: Sanofi, Sanofi Mature IP, Sanofi Biotechnology SAS (France), Sanofi-Aventis Deutschland GmbH (Germany), Ablynx (Belgium), Genzyme Corporation, Bioverativ Inc., Kadmon Corporation LLC , Amunix Pharmaceuticals, Inc., Kymab Ltd